Monitor the company's cash runway and clinical trial progress for pemvidutide. The dilution from this offering may pressure the stock price near term, but successful trial results could offset this.
Price Chart
Executive Summary
Altimmune is raising $211.5 million through a public offering of 64.25 million shares of common stock and 75 million common stock warrants, priced at $3.00 per share. The proceeds will fund the Phase 3 trial of pemvidutide for MASH and general corporate purposes. This is a dilutive capital raise following a recent share authorization increase.
Key Financial Metrics
Key Facts
- Altimmune is raising $211.5 million through a public offering
- The offering consists of 64.25 million shares of common stock and 75 million common stock warrants
- The shares and warrants are priced at $3.00 per share
- Proceeds will fund the Phase 3 trial of pemvidutide for MASH and general corporate purposes
- This offering follows a recent shelf registration and a charter amendment to increase authorized shares
Financial Impact
$211.5 million raised through issuance of 64.25 million shares and 75 million warrants at $3.00 per share
Risk Factors
- Significant shareholder dilution from issuing over 139 million new securities
- Clinical trial failure risk for pemvidutide in MASH
- Dependence on successful execution of Phase 3 trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-048552 |
| Document: tm2612493d2_ex4-1.htm | 0001104659-26-048552 |
| Document: tm2612493d2_ex4-2.htm | 0001104659-26-048552 |
| Document: tm2612493d2_8k.htm | 0001104659-26-048552 |
| Document: tm2612493d2_ex5-1.htm | 0001104659-26-048552 |
| Document: 0001104659-26-048552-index-headers.html | 0001104659-26-048552 |
| Document: 0001104659-26-048552-index.html | 0001104659-26-048552 |
| Document: 0001104659-26-048552.txt | 0001104659-26-048552 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $2.97 $2.67 | ▼ −10.10% | ▼ −12.05% | $2.09 (−29.63%) |
Aug 12, 2026 10w ago | 8-K | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 12, 2026 10w ago | Press Release | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 6, 2026 11w ago | Institutional Cluster | $3.01 $2.88 | ▼ −4.32% | ▼ −5.53% | $2.09 (−30.56%) |
Aug 5, 2026 11w ago | Press Release | $3.03 $2.93 | ▼ −3.30% | ▼ −3.65% | $2.09 (−31.02%) |
Aug 3, 2026 12w ago | Press Release | $3.00 $3.05 | ▲ +1.67% | ▼ −0.36% | $2.09 (−30.33%) |
Jul 28, 2026 12w ago | 8-K | $2.99 $3.00 | ▲ +0.33% | ▼ −1.93% | $2.09 (−30.10%) |
May 28, 2026 21w ago | Press Release | $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.09 (−31.92%) |
May 27, 2026 21w ago | Press Release | $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.09 (−29.87%) |
May 13, 2026 23w ago | 8-K | $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.09 (−30.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers